Cargando…

Intravenous immunoglobulin therapy for COVID-19 ARDS

Detalles Bibliográficos
Autores principales:	Wilfong, Erin M, Matthay, Michael A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585495/ https://www.ncbi.nlm.nih.gov/pubmed/34774186 http://dx.doi.org/10.1016/S2213-2600(21)00450-1

Ejemplares similares

Importance of predicting non-response to intravenous immunoglobulin therapy in non-Asian patients with Kawasaki disease
por: Koné-Paut, Isabelle, et al.
Publicado: (2022)

Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs
por: Crosby, Laura, et al.
Publicado: (2021)

Cytokine adsorption during ECMO for COVID-19-related ARDS
por: Shekar, Kiran, et al.
Publicado: (2021)

Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
por: Prohaska, Stefanie, et al.
Publicado: (2018)

Higher PEEP in intubated COVID-19-associated ARDS patients? We are not sure
por: Yaroshetskiy, Andrey I., et al.
Publicado: (2022)

Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
por: Matthay, Michael A, et al.
Publicado: (2020)

Interleukin-6 inhibitors in non-COVID-19 ARDS: analyzing the past to step into the post-COVID-19 era
por: Gandini, Lucia, et al.
Publicado: (2023)

COVID-19-related ARDS: one disease, two trajectories, and several unanswered questions
por: Lascarrou, Jean-Baptiste
Publicado: (2021)

Investigation of cardiac adverse effects in COVID-19 ARDS patients treated with intravenous immunoglobulin
por: Ayyildiz, Ayse, et al.
Publicado: (2023)

Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms
por: Pain, Clare E, et al.
Publicado: (2020)

Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
por: Shetty, Ashok K., et al.
Publicado: (2021)

Treatment for severe acute respiratory distress syndrome from COVID-19
por: Matthay, Michael A, et al.
Publicado: (2020)

ECMO for severe ARDS associated with COVID-19: now we know we can, but should we?
por: Shekar, Kiran, et al.
Publicado: (2020)

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19
por: So-Osman, Cynthia, et al.
Publicado: (2022)

β-agonists for ARDS: the dark side of adrenergic stimulation?
por: Thompson, B Taylor
Publicado: (2012)

Immunoglobulin, glucocorticoid, or combined therapy for multisystem inflammatory syndrome in children
por: Chew, Christine, et al.
Publicado: (2023)

Time-controlled adaptive ventilation in patients with ARDS—lack of protocol adherence: a systematic review
por: Katzenschlager, Stephan, et al.
Publicado: (2023)

ECMO in severe acute respiratory distress syndrome
por: Matthay, Michael A
Publicado: (2019)

Why compliance and driving pressure may be inappropriate targets for PEEP setting during ARDS
por: Grieco, Domenico Luca, et al.
Publicado: (2022)

Intravenous immunoglobulin therapy in COVID-19-related encephalopathy
por: Muccioli, Lorenzo, et al.
Publicado: (2020)

Proinflammatory cytokines and ARDS pulmonary edema fluid induce CD40 on human mesenchymal stromal cells—A potential mechanism for immune modulation
por: Wilfong, Erin M., et al.
Publicado: (2020)

Monoclonals for patients hospitalised with COVID-19
por: Pogue, Jason M, et al.
Publicado: (2022)

Passive antibody therapy in COVID-19
por: Abraham, Jonathan
Publicado: (2020)

CD24Fc: an emerging COVID-19 therapy
por: Eckhardt, Christina M, et al.
Publicado: (2022)

COVID-19 and systemic anticancer therapy: exploiting uncertainty
por: Gelderblom, Hans, et al.
Publicado: (2021)

COVID-19 and health care inaccessibility in sub-Saharan Africa
por: Hulland, Erin
Publicado: (2020)

COVID-19: immunopathology and its implications for therapy
por: Cao, Xuetao
Publicado: (2020)

The opening salvo of anti-complement therapy against COVID-19
por: Campbell, Courtney M
Publicado: (2020)

On the relevance of outpatient intravenous iron therapy for anemia management
por: Muñoz, Manuel
Publicado: (2011)

Who, what, and when—effective therapy for severe COVID-19
por: Kelmenson, Daniel A, et al.
Publicado: (2022)

Endothelial biomarkers in human sepsis: pathogenesis and prognosis for ARDS
por: Hendrickson, Carolyn M., et al.
Publicado: (2018)

No perfect therapy for the imperfect COVID-19 cytokine storm
por: Cron, Randy Q
Publicado: (2022)

COVID-19: ACT trials for colchicine and antithrombotic therapies
por: Barco, Stefano, et al.
Publicado: (2022)

Electroconvulsive therapy practice during the COVID-19 pandemic
por: Bellini, Helena, et al.
Publicado: (2020)

Convalescent plasma as a potential therapy for COVID-19
por: Chen, Long, et al.
Publicado: (2020)

Kidney involvement in COVID-19 and rationale for extracorporeal therapies
por: Ronco, Claudio, et al.
Publicado: (2020)

Is IL-6 a key cytokine target for therapy in COVID-19?
por: Jones, Simon A., et al.
Publicado: (2021)

Intravenous immunoglobulin G therapy for neonatal hyperbilirubinemia
por: Rasiah, Saisujani, et al.
Publicado: (2023)

Off-label therapy targeting pathogenic inflammation in COVID-19
por: Romani, Luigina, et al.
Publicado: (2020)

Challenges in lung cancer therapy during the COVID-19 pandemic
por: Calabrò, Luana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8rgg31rod11bssacqoegcd88ii